Key Laboratory for Bioarcheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing 400044, China.
Chongqing University Three Gorges Hospital, Chongqing Municipality Clinical Research Center for Endocrinology and Metabolic Diseases, Chongqing 404000, China.
ACS Appl Mater Interfaces. 2024 Sep 4;16(35):46578-46589. doi: 10.1021/acsami.4c07720. Epub 2024 Aug 22.
Atherosclerosis (AS) is characterized by the accumulation of lipids within the walls of coronary arteries, leading to arterial narrowing and hardening. It serves as the primary etiology and pathological basis for cardiovascular diseases affecting the heart and brain. However, conventional pharmacotherapy is constrained by inadequate drug delivery and pronounced toxic side effects. Moreover, the inefficacy of nanomedicine delivery systems in controlling disease progression may be attributed to nonspecific clearance by the mononuclear phagocyte system. Thus, a biomimetic platform spontaneously enveloped by red blood cell membrane is exploited for anti-atherosclerosis applications, offering favorable biocompatibility. The CLIKKPF polypeptide is introduced to develop red blood cell membrane spontaneously encapsulated nanotherapeutics only through simple coincubation. Given the functional modifications, RBC@P-LVTNPs is beneficial to facilitate the target drug delivery to the atherosclerotic lesion, responding precisely to the pathological ROS accumulation, thereby accelerating the on-demand drug release. Both and results also confirm the significant therapeutic efficacy and favorable biocompatibility of the biomimetic nanomedicine delivery system, thus providing a promising candidate for nanotherapeutics against AS.
动脉粥样硬化（AS）的特征是冠状动脉壁内脂质的积累，导致动脉变窄和硬化。它是影响心脏和大脑的心血管疾病的主要病因和病理基础。然而，传统的药物治疗受到药物输送不足和明显的毒性副作用的限制。此外，纳米医学输送系统在控制疾病进展方面的无效性可能归因于单核吞噬细胞系统的非特异性清除。因此，利用仿生平台，即自发被红细胞膜包裹的平台，用于抗动脉粥样硬化应用，提供良好的生物相容性。引入 CLIKKPF 多肽，通过简单的共孵育即可开发出仅由红细胞膜自发包裹的纳米治疗药物。由于功能修饰，RBC@P-LVTNPs 有利于促进靶向药物递送到动脉粥样硬化病变部位，对病理 ROS 积累做出精确响应，从而加速按需药物释放。 和 结果也证实了仿生纳米医学输送系统的显著治疗效果和良好的生物相容性，因此为针对 AS 的纳米治疗提供了有前途的候选药物。
